Advitech's Dermylex enters the Austrian market


    QUEBEC CITY, June 11 /CNW Telbec/ - Advitech Inc. ("Advitech" or the
"Corporation") (TSX Venture Exchange: AVI) today announces the execution of an
exclusive agreement with Pelpharma Handels GmbH ("Pelpharma") for the
distribution of Dermylex(R) in Austria.
    This agreement with Pelpharma is for an initial three-year term and may
be renewed. It grants Pelpharma exclusivity for the Austrian market, and it
includes minimum yearly commitment levels for the purchase of Dermylex(R).
    Austria has a population of over 8 million people and Pelpharma has a
dedicated sales force network that reaches to over 600 dermatologists.
Pelpharma's dedicated work force is, in the Corporation's opinion,
strategically positioned to penetrate the dermatologists and paediatricians
market. Pelpharma is totally focused on dermatological issues that incorporate
the complete coverage of the Austrian market. "We are very happy to be
represented by Pelpharma which, we believe, has the capacity to successfully
market Dermylex(R) in Austria" said Renaud Beauchesne, Executive Chairman at
    "The market of dietary supplements having special medical purpose is an
interesting market, not only in Austria, but in Europe as well. The addition
of Dermylex(R) to the existing Pelpharma portfolio is an excellent opportunity
for us to enter this marketplace and create new revenues" said Nicki Peljak,
President at Pelpharma.


    Pelpharma is a 100% privately owned pharmaceutical company operating in
Austrian dermatology markets. Its owner has more than 20 years of experience
in dermatology, the sole focus of Pelpharma. The major part of the company's
sales is achieved with dermatological drugs needing prescription. The product
portfolio consists partly of generic products where Pelpharma is the holder of
registration and partly of in-licensed products from companies who do not have
their own distribution in Austria.


    Advitech is a health sciences and technology company with a mission to
discover and commercialize proprietary and evidence-based natural health
products. Effective and safe, these products play a role in the prevention of
immune-mediated inflammatory disorders, such as psoriasis and inflammatory
bowel disease. Advitech produces Dermylex(R) for the treatment of
mild-to-moderate psoriasis.
    Advitech has initiated an innovative wound healing research program to
develop new applications for both its XP-828L and IM technological platforms.

    This press release contains forward-looking statements, which reflect the
Corporation's current expectations regarding future events. The
forward-looking statements involve risks and uncertainties. Actual results
could differ materially from those projected herein. The TSX Venture Exchange
does not accept responsibility for the adequacy or accuracy of this release.
    %SEDAR: 00021006EF

For further information:

For further information: Renaud Beauchesne, MBA, Executive Chairman,
Advitech Inc., (418) 686-7498, ext. 228,; Serge Comeau,
Investor's relations, Advitech Inc., (514) 862-4160,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890